Ionis Pharmaceuticals Inc. - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Ionis Pharmaceuticals, Inc. is a fully integrated commercial-stage biotechnology company focused on RNA-targeted therapeutics. The company operates as a single segment and is transitioning into independent commercialization of its medicines while maintaining strategic partnerships for development and commercialization of other assets.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $246.1 million | $131.6 million |
| Net Loss | $(92.5) million | $(146.9) million |
| Loss Per Share (Basic & Diluted) | $(0.56) | $(0.93) |
| Cash, Cash Equivalents & Short-Term Investments | $1.92 billion | $2.57 billion (Dec 31, 2025) |
| Operating Cash Flow | $(792.8) million | $(150.8) million |
| Long-Term Debt (Principal) | $1.345 billion | $1.345 billion |
Note: Operating cash flow usage in Q1 2026 was significantly impacted by a $632.5 million escrow deposit for the maturity of 0% convertible senior notes due April 2026.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 87% year-over-year, driven by a 42% increase in commercial revenue and a 149% increase in R&D revenue.
- Commercial Sales: Product sales, net, surged to $43.0 million from $6.3 million, primarily due to the launch of DAWNZERA (August 2025) and continued sales of TRYNGOLZA.
- R&D Milestones: R&D revenue included significant milestone payments: $50 million from Roche (Phase 1 initiation for Alzheimer's), $30 million from GSK (regulatory filings for bepirovirsen), and $15 million from Otsuka (DAWNZERA EU approval).
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose to $150.4 million from $76.3 million, reflecting investments in commercialization infrastructure for TRYNGOLZA and DAWNZERA.
- Investment Gains: The company recorded a net gain on investments of $22.6 million, compared to a loss of $2.2 million in the prior year, largely due to the fair value adjustment of a private equity investment that went public.
Outlook, Risks, and Unusual Items
- Debt Maturity: The company held $632.5 million in escrow for the 0% convertible senior notes due April 2026. These notes were repaid in April 2026 using the escrow funds and proceeds from a 2025 offering.
- Regulatory Catalysts: The FDA has granted Priority Review for olezarsen (sHTG) with a PDUFA date of June 30, 2026, and zilganersen (Alexander disease) with a PDUFA date of September 22, 2026.
- Legal Proceedings: Ionis is engaged in ongoing patent litigation with Arrowhead Pharmaceuticals regarding plozasiran, with Arrowhead filing counterclaims asserting patent invalidity.
- Risk Factors: Key risks include the ability to successfully commercialize independently launched medicines, dependence on partners (Biogen, AstraZeneca, GSK) for other assets, and potential impacts of new U.S. tariffs on imported pharmaceutical products announced in April 2026.
Investor Verification Checklist
- Commercial Execution: Verify the uptake and reimbursement status of DAWNZERA and TRYNGOLZA in the U.S. market.
- Regulatory Decisions: Monitor FDA decisions on olezarsen (June 2026) and zilganersen (September 2026).
- Debt Structure: Confirm the extinguishment of the 0% Notes due 2026 and the terms of the remaining 0% Notes due 2030 and 1.75% Notes due 2028.
- Partnership Milestones: Track progress on bepirovirsen (GSK) and WAINUA (AstraZeneca) for potential future milestone payments.
- Legal Exposure: Assess the potential financial impact of the patent dispute with Arrowhead Pharmaceuticals.